Exhibit 107
Calculation of Filing Fee Tables
424(b)(5)
(Form Type)
Apellis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Rule |
Amount Registered |
Proposed Offering Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Fee | |||||||||
| Newly Registered Securities | ||||||||||||||||
| Fees to be Paid |
Equity | Common Stock, par value $0.0001 per share | 457(r) | 6,388,892(1) | $63.00 | $402,500,196(1) | 0.00011020 | $44,355.53(2) | ||||||||
| Fees to be Paid |
Equity | Pre-funded warrants to purchase common stock(3) | 457(r) | 2,380,956(1 | $62.9999(4) | $—(5) | 0.00011020 | $—(2) | ||||||||
| Fees Previously Paid |
— | — | — | — | — | — | ||||||||||
| Carry Forward Securities | ||||||||||||||||
| Carry Forward Securities |
— | — | — | — | — | |||||||||||
| Total Offering Amounts | $402,500,196 | $44,355.53 | ||||||||||||||
| Total Fees Previously Paid | $— | |||||||||||||||
| Total Fee Offsets | $27,810(6) | |||||||||||||||
| Net Fee Due | $16,545.53(6) | |||||||||||||||
Table 2: Fee Offset Claims and Sources
| Registrant or Filer Name |
Form or Filing Type |
File Number |
Initial Filing Date |
Filing Date |
Fee Offset Claimed |
Security Type Associated with Fee Offset Claimed |
Security Title Associated with Fee Offset Claimed |
Unsold Securities Associated with Fee Offset Claimed |
Unsold Aggregate Amount with Fee Offset Claimed |
Fee Paid with Fee Offset Source | ||||||||||||
| Rule 457(p) | ||||||||||||||||||||||
| Fee Offset Claims |
Apellis Therapeutics, Inc. | 424(b)(5) | 333-235830 | January 20, 2022 | $27,810(3) | Common |
(3) | (3) | $300,000,000 | — | ||||||||||||
|
Fee Offset Sources |
Apellis Therapeutics, Inc. | 424(b)(5) | 333-235830 | — | January 20, 2022 | — | — | — | — | — | $27,810(6) | |||||||||||
| (1) | Assumes exercise in full of the underwriters’ option to purchase up to 833,333 additional shares of common stock and includes 2,380,956 shares of common stock issuable upon exercise of the pre-funded warrants to purchase common stock. |
| (2) | In accordance with Rule 457(r) under the Securities Act. This “Calculation of Filing Fee Tables” table shall be deemed to update the “Calculation of Registration Fee” table in the registrant’s Registration Statement on Form S-3 (File No. 333-269899) in accordance with Rule 456(b) and 457(r) under the Securities Act of 1933 |
| (3) | Pursuant to Rule 416 under the Securities Act, the pre-funded warrants to purchase common stock being registered hereunder include such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of share splits, share dividends or similar transactions. |
| (4) | The registration fee for the pre-funded warrants is being allocated to the shares of common stock issuable upon exercise of the pre-funded warrants. |
| (5) | Represents the sum of the public offering price of the pre-funded warrants of $62.9999 per pre-funded warrant and the exercise price of $0.0001 per share issuable pursuant to the pre-funded warrants. |
| (6) | On January 20, 2022, the registrant filed a prospectus supplement dated January 20, 2022 pursuant to Rule 424(b(5) of the Securities Act (the “2022 prospectus supplement”), which supplemented the base prospectus included in the registrant’s registration statement on Form S-3 (File No. 333-235830) filed on January 7, 2020. The registrant registered an aggregate of $300,000,000 of securities under the 2022 prospectus supplement, representing $27,810 in registration fees, and sold $0 of securities under the 2022 prospectus supplement. The offering under the 2022 prospectus supplement been terminated. |
Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the securities being registered hereby in the amount of $44,355.53 is offset by $27,810 in registration fees previously paid by the registrant with respect to 2022 prospectus supplement that were registered but not sold prior to termination of the offering. Accordingly, $16,545.53 in registration fees are being paid in connection with this prospectus supplement